Pharmacopeia Inc.

N.v. Organon

Merck Sharp + Dohme B.v.

Msd Oss B.v.

Pharmacopeia Drug Discovery, Inc.

Jui-Hsiang Chan

Michael H Ohlmeyer

Irina Neagu

Koc-Kan Ho

Nasrin Ansari

Jeffrey John Letourneau

David Jonathan Bennett

Michelle Lee Morris

Christopher Mark Riviello

John Richard Morphy

Patrick Anthony Jokiel

Yajing Rong

Susan Elizabeth Napier

Andrew Stanley Edwards

Andrew John Cooke

Andrew Roughton

Andrew Cooke

Andrew Laird Roughton

Koc-Kan Hoc

The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by hydroxy, cyano or halogen; Rrepresents 1 or 2 optional halogens; Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism. 

1-(4-ureidobenzoyl)piperazine derivatives

The present invention relates to N-benzyl,N'-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N&#x2032;-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.

N-benzyl,N'-arylcarbonylpiperazine derivatives

Disclosed herein are 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivative of formula I, or pharmaceutically acceptable salts or solvates thereof wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives according to the present invention and their use in therapy.

[object Object]

The present invention relates to 2-(4-oxo4H-quinazolin-3-yl) acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression. 

2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists

Growing community of inventors

West Windsor, NJ, United States of America

Jui-Hsiang Chan